(Kevin Dietsch/Getty Images)

Analyst: “Longer-term vectors that drive the stock’s value” haven’t changed for Tesla

A longtime Tesla bull on yesterday’s market meshugas.

6/6/25 11:39AM

Longtime Tesla bull Adam Jonas of Morgan Stanley is out with a note putting a characteristically optimistic spin on yesterday’s high-profile feud between Elon Musk and the president. He writes:

“1. Credits. We do not believe the phasing out of EV tax credits from the BBB (Big Beautiful Bill) is material to the long term outlook for TSLA.
2. Distraction. We believe Tesla’s recent 50% rally was driven primarily by hopes that Elon Musk would refocus time and attention on Tesla.
3. Cars. While the situation remains fluid, we believe the disagreement will not help Tesla demand but could potentially (temporarily) alienate multiple sides of the political spectrum.
4. Bigger picture. While emotions are running high, we are not convinced the longer-term vectors that drive the stock’s value have changed here. AI leadership, autonomy/robotics, manufacturing, supply chain re-architecture, renewable power, critical infrastructure... Tesla still holds so many valuable cards that are largely apolitical, in our opinion.
5. Volatility. When putting our trading cap on, we have higher conviction in near-term volatility than near-term direction. We reiterate our $410 price target but are prepared for the stock to give up more than just the 4 weeks of performance it has sacrificed so far.”

True-to-form Jonas remains one of the most optimistic Wall Street analysts on the company, with a $410 share price on the stock, about a 35% premium to where the stock was trading midday Friday and far higher than the Wall Street consensus price target of $308.

Jonas writes that his optimism is based on his “belief that Tesla’s capabilities in key areas of physical AI (autonomous vehicles, humanoids and other form factors) including data, robotics, energy storage, compute, manufacturing and space/comms/networking/infrastructure offer growth and margin opportunities that greatly exceed those of the traditional EV business,” adding that “the challenges facing Tesla’s current business are widely reported and well known, while the opportunities in the future business are potentially greatly underestimated.”

Matt Phillips

40m

Tempus AI jumps on FDA clearance of AI-enabled tool to analyze cardiac MRIs

Tempus AI, a midcap medical diagnostics company that’s highlighted a push to incorporate AI technology into its products, surged on Thursday after announcing the FDA had issued a “510(k) clearance” of a new AI-enabled tool to analyze cardiac imagery from MRIs.

A 510(k) clearance — used for devices that are considered relatively low risk — essentially allows a product to be sold in the US.

While the company has never turned a profit, even on an adjusted basis, its sales are growing rapidly and the stock has had a great year, rising more than 160% in 2025.

For more on the company, check out our interview with its CEO, Eric Lefkofsky.

Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device

While the company has never turned a profit, even on an adjusted basis, its sales are growing rapidly and the stock has had a great year, rising more than 160% in 2025.

For more on the company, check out our interview with its CEO, Eric Lefkofsky.

Luke Kawa

Micron surges as Citi boosts price target to $175

Micron is on the move this morning, gapping higher and continuing to trade up double digits after Citi boosted its view on how much the shares can run.

Analyst Christopher Danely raised his price target on the memory chipmaking specialist to $175 from $150, while maintaining a “buy” rating. The average analyst price target of $151 has now been shattered by Micron’s rise today, and the stock is trading at its highest level since June 2024.

This continues Micron’s advance as OpenAI’s dogged determination to burn through cash to enhance its AI capabilities provides a broad lift to the space, punctuated by Oracle’s massive gain on Wednesday.

Call demand is running hot: just 13 minutes into the session, volumes are running at 106,157 compared to a 20-day average of 88,888.

Micron is slated to report quarterly results on September 23.

J. Edward Moreno

Centene rises after affirming full-year guidance

Centene soared in early trading after affirming its full-year guidance ahead of the Deutsche Bank 2025 Healthcare Summit on Thursday.

The company reiterated its expectation for adjusted diluted earnings per share to be approximately $1.75. At the conference, Centene executives also said they expect a higher percentage of its Medicare enrollees to be on more lucrative, top-rated plans next year, according to Bloomberg.

Earlier this week, UnitedHealth also reiterated its guidance and said it expects to have more top-rated plans in the coming year. The government rates insurance companies offering Medicare Advantage plans, and higher-rated plans are eligible for bonuses that can significantly increase a plan’s revenue.

Insurance companies that sell government-sponsored plans took a dive earlier this year amid unexpected rising costs. The recent announcements from both Centene and UnitedHealth may be a sign that the worst is behind them.

Max Knoblauch

Delta boosts its third-quarter sales outlook on improved travel demand

Delta Air Lines reaffirmed its full-year earnings outlook on Thursday, seeing US travel demand hold strong for the rest of the year.

Citing “improved demand trends,” the airline also elevated its sales forecast for the third quarter to an increase of between 2% and 4%. In July, it guided for 0% to 4% growth.

The move marks a turnaround from just five months ago, when Delta and many of its rivals pulled their full-year earnings outlooks as growth stalled on “broad economic uncertainty.” At the beginning of the year, Delta said 2025 had the chance to be its best fiscal year in a century.

After plunging earlier this year, Delta’s shares are essentially flat in 2025.

Hyunsoo Rim

Oracle’s rally briefly made cofounder Larry Ellison the world’s richest person, ahead of Elon Musk

Oracle pulled off one of the biggest rallies in its stock market history, as shares soared 36% on Wednesday after the company laid out a cloud business growth forecast that left analysts “blown away.”

What also went vertical, alongside the stock, was cofounder Larry Ellison’s fortune.

According to the Bloomberg Billionaires Index, Ellison’s net worth jumped by a record $89 billion to $383 billion, the biggest single-day gain ever, briefly overtaking Elon Musk’s fortune and making him, for a moment, the world’s richest person. Musk reclaimed the top spot by the end of Wednesday.

Yesterday’s remarkable gain means that Larry Ellison has now seen his estimated wealth increase by $191 billion year to date. That’s the equivalent of making $752 million a day, more than $522 thousand a minute, or $8,703 per second.